-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Long Island Capital Alliance to Host Technology Capital Forum
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Who Is the Best MTF Top Surgeon?
-
APPA Launches 2026 Pet Industry Holiday Gift Guide, Backed by New Pet Gifting Data
-
United Bancorp, Inc. Increases its Fourth Quarter Cash Dividend Payment to $0.20 per Share, which Produces a Forward Yield of 5.4%
-
moveBuddha Doubles Moving Company Database to More Than 9,000 U.S. Movers
-
Montlick Injury Attorneys Brings Literacy and Lifesaving Booster Seat Safety Lessons to Atlanta Students
-
Mesothelioma Hope Remembers "Captain Dale" Perkins, Whose Story Reflects the Power of Connection and Support
-
Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money
-
BHG Financial Celebrates 25 Years of Innovation with Women in Technology Panel and Donates to Girls Who Code
-
Two Couples Will Win Valentine's Day Weddings at Love in Times Square Presented by David's Bridal
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Kolter Homes Introduces New Nancy Floorplan at Woodland Preserve in Parrish, Florida
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security.
"The delivery of the first made-in-Canada mRNA vaccines to provinces and territories across the country marks a major milestone in our partnership with Canada," said Stéphane Bancel, Chief Executive Officer of Moderna. "This is not just about local manufacturing, it's about scientific leadership, national health security and ensuring Canadians have timely access to the latest mRNA medicines. We're proud to stand alongside Canada in advancing innovation, driving economic growth and investing in a resilient future for public health."
All drug substance of Moderna's authorized Spikevax® (COVID-19 mRNA vaccine) product targeting the SARS-CoV-2 LP.8.1 variant is manufactured at the facility in Laval, Quebec. Fill-and-finish of the new single-use pre-filled syringes is completed by Novocol Pharma in Cambridge, Ontario.
Moderna's updated COVID-19 vaccine targeting the LP.8.1 variant was approved by Health Canada on August 21, 2025 [1], and has also received authorization from regulators in the United States, Europe, Japan, Switzerland and several other countries. Additional regulatory submissions are under review globally in preparation for the 2025-2026 respiratory virus season.
Canadian Access and Eligibility
Timing and eligibility for the COVID-19 public vaccination program in Canada is set by each province and territory. Those who meet provincial criteria will receive COVID-19 vaccines free of charge. For individuals not covered under the public programs, efforts are ongoing with private insurers and payers to streamline access and reimbursement within the private sector. Canadians are encouraged to consult their provincial or territorial health authorities for the latest information on eligibility and availability.
Additional Quotes:
Stefan Raos, General Manager, Moderna Canada, said:
"As a Canadian, it's incredibly meaningful to see our first made-in-Canada COVID-19 vaccines in pre-filled syringes now reaching across the country to help protect Canadians starting this fall. This marks a critical shift, demonstrating that Canada's domestic manufacturing capability is real, operational and serving Canadians today. It reflects what's possible when science, industry and government work together with purpose."
The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, said:
"Today's milestone of the production of the first made-in-Canada doses of Moderna's COVID-19 vaccine represents a major achievement for Canada's biomanufacturing and life sciences sector. Our government is building a resilient, forward-looking economy that positions Canada as a global leader in scientific research and innovation. Moderna's investments in Canada strengthen our national life sciences industry, create good-paying new jobs for Canadians and bolster our national security."
The Honourable Marjorie Michel, Minister of Health, said:
"Manufacturing the first-ever doses of a fully made-in-Canada COVID-19 vaccine demonstrates the power of collaboration between government, industry and science to help protect the health of Canadians. By producing vaccines here at home, we are supporting our economy while strengthening Canada's ability to respond quickly and effectively to future public health emergencies."
Images and b-roll can be found here.
[1] Moderna Canada. SPIKEVAX® Product Monograph. August 21, 2025.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Spikevax® is a registered trademark of Moderna.
Moderna Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the availability in Canadian provinces and territories of Moderna's updated COVID vaccine for the 2025-2026 vaccination season; Moderna's Canadian manufacturing; and Moderna's pending regulatory applications for approval of its COVID vaccine globally. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Sacha Kennedy
Director, Communications and Media
+1 647-385-6846
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
K.Hill--AT